Tempus AI (NASDAQ:TEM) Shares Down 4.3% - Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price was down 4.3% on Tuesday . The stock traded as low as $48.87 and last traded at $49.62. Approximately 3,190,208 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 9,131,566 shares. The stock had previously closed at $51.86.

Wall Street Analyst Weigh In

TEM has been the subject of a number of research reports. Piper Sandler reissued a "neutral" rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Guggenheim initiated coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a "buy" rating and a $74.00 price target on the stock. Finally, Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Remove Ads

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company's 50 day moving average price is $44.21 and its two-hundred day moving average price is $48.03.

Insider Activity at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 120,000 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the completion of the transaction, the chief operating officer now directly owns 1,007,207 shares of the company's stock, valued at $42,816,369.57. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the completion of the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at $358,780,403.82. This trade represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862,758 shares of company stock worth $79,585,675.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $256,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 166.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock valued at $109,352,000 after acquiring an additional 2,021,394 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Tempus AI in the 4th quarter worth $178,000. James J. Burns & Company LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth $236,000. Finally, abrdn plc bought a new stake in Tempus AI during the fourth quarter valued at about $2,784,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.